Global Partners LPNYSE: GLP

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed.

After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets.

Global Partners LP Common Units (NYSE:GLP ) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Sean Geary - CLO & Secretary Conference Call Participants Selman Akyol - Stifel Operator Good day, everyone, and welcome to the Global Partners Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded.

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading after the strong Q3 results and raised outlook (~8 points higher on growth and 2 points of additional adjusted EBITDA margin). HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to direct-to-consumer models.

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-loss drugs continue to draw subscribers.

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study"). Blood Sugar Levels (mmol/L) DehydraTECH Groups Day 7 Baseline Day 28 % Change to Day 28 Day 56 % Change to Day 56 Day 84 % Change to Day 84 A: CBD1 27.4 26.2 -4.31% 26.9 -1.90% 27.7 1.09% B: CBD2 28.4 29.2 2.73% 26.6 -6.22% 27.3 -3.76% C: CBD3 26.4 24.9 -5.99% 27.1 2.46% 27.5 3.85% D: CBD4 24.6 27.9 13.16% 26.8 8.94% 27.0 9.75% E: Rybelsus1 26.4 25.5 -3.60% 26.8 1.33% 26.8 1.59% w/SNAC F: Rybelsus2 24.9 26.8 7.70% 26.4 5.96% 27.3 9.58% w/SNAC G: Semaglutide 26.3 25.9 -1.52% 27.8 5.54% 26.9 2.13% No SNAC H: Liraglutide 26.4 25.8 -2.08% 25.2 -4.56% 23.3 -11.54% No SNAC Notes - Groups A through D were different DehydraTECH-CBD compositions - Groups E and F were reformulated Rybelsus DehydraTECH compositions - Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively) in DehydraTECH compositions - Recalculations led to slight changes from earlier reported data Lexaria is strongly encouraged that the DehydraTECH-liraglutide and DehydraTECH-CBD groups A and B outperformed all three of the Rybelsus® and pure semaglutide DehydraTECH composition groups regardless of whether the semaglutide had or had not been processed with the salcaprozate sodium technology known as "SNAC".

Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and early sales success, Madrigal's Q3 earnings will be crucial in determining Rezdiffra's commercial viability and stock performance. The potential for Rezdiffra to achieve blockbuster status is tempered by its high cost and the emerging threat of GLP-1 agonists in the MASH market.

Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.

Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis.